Conference Reports for NATAP

Back

The Liver Meeting AASLD 2026 Nov 5-8 Denver   This information is brought to you by NATAP and is not sponsored by, nor a part of, the American Association for the Study of Liver Diseases or The Liver Meeting® or The Liver Meeting Digital Experience ™     Positive Phase 3 IDEAL Study Results Further Support Livdelzi®'s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC) - (11/05/26)   Liver Fibrosis - fatty Liver, MASLD Updated Early and Week 52 Biomarker (MRI-PDFF, ALT, MRE and PRO-C3) Responses to Resmetirom Associate With Improvements in MASH and Liver Fibrosis - (11/08/26)   Hepatitis B Rates of functional cure in participants with chronic hepatitis B virus infection treated with bepirovirsen: B-Well Phase 3 trials end of study results - (11/08/26)   Rates of functional cure in participants with chronic hepatitis B virus infection treated with bepirovirsen: B-Well Phase 3 trials end of study results - (11/08/26)   Bepirovirsen B-Well Phase 3 trials: Predicting functional cure rates based upon hepatitis B surface antigen at Week 12 - (11/07/26)   Bepirovirsen B-Well Phase 3 trials: Predicting functional cure rates based upon hepatitis B surface antigen at Week 12 - (11/07/26)   Hepatitis D BULEVIRTIDE MONOTHERAPY PREVENTS LIVER DECOMPENSATION IN HDV-RELATED CIRRHOSIS: 3-YEAR RESULTS FROM A EUROPEAN, RETROSPECTIVE, CONTROLLED COHORT STUDY oral - (11/08/26)   BULEVIRTIDE MONOTHERAPY PREVENTS LIVER DECOMPENSATION IN HDV-RELATED CIRRHOSIS: 3-YEAR RESULTS FROM A EUROPEAN, RETROSPECTIVE, CONTROLLED COHORT STUDY - (11/08/26)   Integrated Efficacy Analysis of Bulevirtide 10 mg Monotherapy in Patients With Chronic Hepatitis Delta 96 Weeks - (11/07/26)   Hepatitis C Implementation of a Test-and-Treat Model for HCV Care Using Point-of-Care HCV RNA Testing in La Bodega - (11/08/26)   Direct-Acting Antiviral Therapy Is Associated With Reduced Cardiovascular, Psychiatric, and Mortality Outcomes in Chronic Hepatitis C: A Propensity Score-Matched Analysis of a Federated Electronic Health Records Network - (11/08/26)   Absolute Survival Benefit of DAA Therapy in Hospitalized Patients with HCV-Related Cirrhosis: A Restricted Mean Survival Time Analysis (MIMIC-IV - (11/08/26)   EVALUATING POSTPARTUM LINKAGE TO HEPATITIS C CARE: RESULTS OF A PATIENT OUTREACH STUDY - (11/08/26)   CASE ASCERTAINMENT RATES FOR CHILDREN INFECTED WITH HEPATITIS C IN FLORIDA Epidemiologic evidence over one decade · May 2016-May 2026 - (11/07/26)   Incentivizing Adherence to Improve Outcomes in a Hepatitis C Virus (HCV) Treatment Trial: Results from the Kentucky Viral Hepatitis Treatment (KeY Treat) Study - (11/07/26)   Evaluating Detection and Outcomes Pre and Post Universal Hepatitis C Screening in Pregnancy Recommendation - (11/07/26)   SHORTER, FASTER: PATIENT CHARACTERISTICS ASSOCIATED WITH 8- VERSUS 12-WEEK SOFOSBUVIR/VELPATASVIR IN AN INCARCERATED HCV COHORT - (11/07/26)   COMPARATIVE EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR VERSUS SOFOSBUVIR/VELPATASVIR IN PATIENTS WITH HEPATITIS C: A MULTICENTER PROSPECTIVE STUDY - (11/07/26)   Real-world impact of drug-drug interactions (DDI): why complex HCV patients are preferentially treated with Sofosbuvir/Velpatasvir (SOF/VEL) over Glecaprevir/Pibrentasvir (GLE/PIB) - (11/07/26)   Does The Presence of NS5A Resistance-Associated Substitution Significantly Affect The SVR Rate? - (11/07/26)   COMPARISON OF EFFICACY BETWEEN 12-WEEK SOFOSBUVIR/VELPATASVIR (SOF/VEL) REGIMEN COMBINED WITH PRE-USE TENOFOVIR ALAFENAMIDE (TAF) FOR HCV/HBV COINFECTION AND SOF/VEL ALONE FOR HCV MONOINFECTION - (11/07/26)   Impact of Direct-Acting Antivirals on Insulin Resistance and Hepatic Steatosis in Treatment-Naïve Chronic HCV-Infected Nondiabetic Patients: A Prospective Study from North India - (11/07/26)   A Case Series on Outcomes of Hepatitis C Infected Patients Who Received Full Course of 84 Tablets of Sofosbuvir/Velpatasvir at the Beginning of Therapy - (11/07/26)   Predictive Value of SVR4 With Glecaprevir/Pibrentasvir in Patients With Cirrhosis, HCV-HIV Coinfection, Recent Injection Drug Use, or Acute Infection - (11/07/26)   Pregnancy Outcomes Following Glecaprevir/Pibrentasvir Exposure in Pregnant Women With Hepatitis C: a Pharmacovigilance Analysis - (11/07/26)   Incidence and Prevalence of Decompensated Cirrhosis Among Patients With Hepatitis C Virus Infection: Pooled Estimates Across US Claims Databases, 2011 to 2023 - (11/07/26)   CARDIOMETABOLIC RISK AND HCC AFTER HCV CURE BY HEPATIC STEATOSIS STATUS: A REAL-C STUDY - (11/05/26)   UNIVERSAL INTEGRATED HBV AND HCV SCREENING IN PRIMARY CARE REVEALS A SUBSTANTIAL HIDDEN BURDEN AND ACHIEVES EXCELLENT LINKAGE TO CARE: A WHO-ALIGNED DECENTRALIZED MODEL - (11/05/26)   RISK FACTORS FOR LIVER-RELATED OUTCOMES AFTER HCV TREATMENT WITH SVR - (11/05/26)   Persistent Risky Alcohol use in Viral Hepatitis Across the PRe- and Post-DAA ERAS: NHANES 1988-2023 - (11/05/26)   Evolving Epidemiology and Disease Burden of Hepatitis C Among US Adults Aged 15-49 Years, 1990-2023 - (11/05/26)   Gender Differences in Stages of Linkage-to-Care Among Patients with Unresolved HCV - (11/05/26)   TARGETED HEPATITIS C PREVENTION, TESTING, AND LINKAGE TO CARE THROUGH CLINIC AND MOBILE OUTREACH IN SOUTHERN NEVADA - (11/05/26)   National Trends and Healthcare Utilization of Chronic Hepatitis C Among Homeless Hospitalizations: A Nationwide Analysis, 2016-2023 - (11/05/26)   Urgen-C: Early Outcomes from a Novel Telehealth HCV Treatment Program for Georgians with Substance Use Disorders - (11/05/26)   Five-Year Mortality, Overdose, and Hepatic Outcomes Associated with Prompt Direct-Acting Antiviral Therapy in Adults with Opioid Use Disorder and Chronic Hepatitis C: A Propensity-Matched Cohort Study - (11/05/26)   De Novo MASLD and Metabolic Outcomes Following DAA-Mediated HCV Eradication: A Propensity Score-Matched Cohort Analysis - (11/05/26)